Download Citation
Article Source:
A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer
Wang S,
Peng L,
Li J,
Zeng X,
Ouyang L,
et al.
(2013)
A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer.
PLOS ONE 8(3): e55917.
https://doi.org/10.1371/journal.pone.0055917